nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—liver cancer	0.456	1	CtDrD
Temsirolimus—MTOR—liver cancer	0.305	1	CbGaD
Temsirolimus—CYP3A7—Sorafenib—liver cancer	0.0241	0.211	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0241	0.211	CbGbCtD
Temsirolimus—CYP3A5—Sorafenib—liver cancer	0.0181	0.158	CbGbCtD
Temsirolimus—ABCB1—Sorafenib—liver cancer	0.0118	0.103	CbGbCtD
Temsirolimus—CYP2D6—Sorafenib—liver cancer	0.0111	0.097	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—liver cancer	0.00714	0.0624	CbGbCtD
Temsirolimus—CYP3A4—Sorafenib—liver cancer	0.00705	0.0617	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—liver cancer	0.00673	0.0588	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—liver cancer	0.00428	0.0374	CbGbCtD
Temsirolimus—Pimecrolimus—MTOR—liver cancer	0.00101	0.303	CrCbGaD
Temsirolimus—Everolimus—MTOR—liver cancer	0.00101	0.303	CrCbGaD
Temsirolimus—Tacrolimus—MTOR—liver cancer	0.000604	0.18	CrCbGaD
Temsirolimus—Sirolimus—MTOR—liver cancer	0.000604	0.18	CrCbGaD
Temsirolimus—Leukopenia—Sorafenib—liver cancer	0.000167	0.00239	CcSEcCtD
Temsirolimus—Blood bilirubin increased—Epirubicin—liver cancer	0.000166	0.00239	CcSEcCtD
Temsirolimus—Creatinine increased—Epirubicin—liver cancer	0.000165	0.00237	CcSEcCtD
Temsirolimus—Cough—Sorafenib—liver cancer	0.000162	0.00233	CcSEcCtD
Temsirolimus—Rectal haemorrhage—Doxorubicin—liver cancer	0.000161	0.00231	CcSEcCtD
Temsirolimus—Viral infection—Doxorubicin—liver cancer	0.000161	0.00231	CcSEcCtD
Temsirolimus—Hypertension—Sorafenib—liver cancer	0.000161	0.00231	CcSEcCtD
Temsirolimus—Cellulitis—Doxorubicin—liver cancer	0.00016	0.0023	CcSEcCtD
Temsirolimus—Hypocalcaemia—Doxorubicin—liver cancer	0.000159	0.00228	CcSEcCtD
Temsirolimus—Arthralgia—Sorafenib—liver cancer	0.000159	0.00227	CcSEcCtD
Temsirolimus—Myalgia—Sorafenib—liver cancer	0.000159	0.00227	CcSEcCtD
Temsirolimus—Herpes simplex—Doxorubicin—liver cancer	0.000158	0.00227	CcSEcCtD
Temsirolimus—Glossitis—Doxorubicin—liver cancer	0.000158	0.00227	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000157	0.00226	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000157	0.00226	CcSEcCtD
Temsirolimus—Pulmonary embolism—Epirubicin—liver cancer	0.000157	0.00226	CcSEcCtD
Temsirolimus—Blood bilirubin increased—Doxorubicin—liver cancer	0.000154	0.00221	CcSEcCtD
Temsirolimus—Cystitis noninfective—Epirubicin—liver cancer	0.000154	0.00221	CcSEcCtD
Temsirolimus—Creatinine increased—Doxorubicin—liver cancer	0.000153	0.00219	CcSEcCtD
Temsirolimus—Cystitis—Epirubicin—liver cancer	0.000152	0.00218	CcSEcCtD
Temsirolimus—Anaphylactic shock—Sorafenib—liver cancer	0.000152	0.00218	CcSEcCtD
Temsirolimus—Infection—Sorafenib—liver cancer	0.000151	0.00217	CcSEcCtD
Temsirolimus—Candida infection—Epirubicin—liver cancer	0.00015	0.00216	CcSEcCtD
Temsirolimus—Fluid retention—Epirubicin—liver cancer	0.000149	0.00214	CcSEcCtD
Temsirolimus—Nervous system disorder—Sorafenib—liver cancer	0.000149	0.00214	CcSEcCtD
Temsirolimus—Thrombocytopenia—Sorafenib—liver cancer	0.000149	0.00213	CcSEcCtD
Temsirolimus—Skin disorder—Sorafenib—liver cancer	0.000148	0.00212	CcSEcCtD
Temsirolimus—Pulmonary embolism—Doxorubicin—liver cancer	0.000146	0.00209	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000146	0.00209	CcSEcCtD
Temsirolimus—Anorexia—Sorafenib—liver cancer	0.000145	0.00208	CcSEcCtD
Temsirolimus—Rash maculo-papular—Epirubicin—liver cancer	0.000143	0.00205	CcSEcCtD
Temsirolimus—Bladder pain—Epirubicin—liver cancer	0.000142	0.00204	CcSEcCtD
Temsirolimus—Ecchymosis—Epirubicin—liver cancer	0.000142	0.00204	CcSEcCtD
Temsirolimus—Mouth ulceration—Epirubicin—liver cancer	0.000142	0.00204	CcSEcCtD
Temsirolimus—Cystitis noninfective—Doxorubicin—liver cancer	0.000142	0.00204	CcSEcCtD
Temsirolimus—Cystitis—Doxorubicin—liver cancer	0.000141	0.00202	CcSEcCtD
Temsirolimus—Candida infection—Doxorubicin—liver cancer	0.000139	0.00199	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000138	0.00199	CcSEcCtD
Temsirolimus—Fluid retention—Doxorubicin—liver cancer	0.000138	0.00198	CcSEcCtD
Temsirolimus—Sepsis—Epirubicin—liver cancer	0.000137	0.00196	CcSEcCtD
Temsirolimus—Dyspnoea—Sorafenib—liver cancer	0.000135	0.00194	CcSEcCtD
Temsirolimus—Rash maculo-papular—Doxorubicin—liver cancer	0.000132	0.0019	CcSEcCtD
Temsirolimus—Decreased appetite—Sorafenib—liver cancer	0.000132	0.00189	CcSEcCtD
Temsirolimus—Thrombophlebitis—Epirubicin—liver cancer	0.000132	0.00189	CcSEcCtD
Temsirolimus—Ecchymosis—Doxorubicin—liver cancer	0.000132	0.00189	CcSEcCtD
Temsirolimus—Mouth ulceration—Doxorubicin—liver cancer	0.000132	0.00189	CcSEcCtD
Temsirolimus—Bladder pain—Doxorubicin—liver cancer	0.000132	0.00189	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000131	0.00188	CcSEcCtD
Temsirolimus—Diabetes mellitus—Epirubicin—liver cancer	0.000131	0.00188	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Sorafenib—liver cancer	0.000131	0.00188	CcSEcCtD
Temsirolimus—Fatigue—Sorafenib—liver cancer	0.000131	0.00188	CcSEcCtD
Temsirolimus—Constipation—Sorafenib—liver cancer	0.00013	0.00186	CcSEcCtD
Temsirolimus—Pain—Sorafenib—liver cancer	0.00013	0.00186	CcSEcCtD
Temsirolimus—Eczema—Epirubicin—liver cancer	0.000127	0.00182	CcSEcCtD
Temsirolimus—Sepsis—Doxorubicin—liver cancer	0.000126	0.00181	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Sorafenib—liver cancer	0.000124	0.00178	CcSEcCtD
Temsirolimus—Thrombophlebitis—Doxorubicin—liver cancer	0.000122	0.00175	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000122	0.00174	CcSEcCtD
Temsirolimus—Diabetes mellitus—Doxorubicin—liver cancer	0.000122	0.00174	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Epirubicin—liver cancer	0.000121	0.00174	CcSEcCtD
Temsirolimus—Body temperature increased—Sorafenib—liver cancer	0.00012	0.00172	CcSEcCtD
Temsirolimus—Abdominal pain—Sorafenib—liver cancer	0.00012	0.00172	CcSEcCtD
Temsirolimus—Dermatitis bullous—Epirubicin—liver cancer	0.00012	0.00171	CcSEcCtD
Temsirolimus—Eczema—Doxorubicin—liver cancer	0.000118	0.00169	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000114	0.00164	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000112	0.00161	CcSEcCtD
Temsirolimus—Hypersensitivity—Sorafenib—liver cancer	0.000112	0.00161	CcSEcCtD
Temsirolimus—Dermatitis bullous—Doxorubicin—liver cancer	0.000111	0.00159	CcSEcCtD
Temsirolimus—Face oedema—Epirubicin—liver cancer	0.00011	0.00158	CcSEcCtD
Temsirolimus—Asthenia—Sorafenib—liver cancer	0.000109	0.00156	CcSEcCtD
Temsirolimus—Tacrolimus—ALB—liver cancer	0.000109	0.0325	CrCbGaD
Temsirolimus—Pruritus—Sorafenib—liver cancer	0.000108	0.00154	CcSEcCtD
Temsirolimus—Blood creatinine increased—Epirubicin—liver cancer	0.000107	0.00154	CcSEcCtD
Temsirolimus—Dehydration—Epirubicin—liver cancer	0.000106	0.00152	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000106	0.00152	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—liver cancer	0.000105	0.0015	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—liver cancer	0.000104	0.00149	CcSEcCtD
Temsirolimus—Diarrhoea—Sorafenib—liver cancer	0.000104	0.00149	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000103	0.00148	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—liver cancer	0.000102	0.00146	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—liver cancer	0.000101	0.00145	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000101	0.00145	CcSEcCtD
Temsirolimus—Dizziness—Sorafenib—liver cancer	0.0001	0.00144	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—liver cancer	9.94e-05	0.00143	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—liver cancer	9.9e-05	0.00142	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—liver cancer	9.87e-05	0.00142	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—liver cancer	9.87e-05	0.00142	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—liver cancer	9.83e-05	0.00141	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—liver cancer	9.69e-05	0.00139	CcSEcCtD
Temsirolimus—Vomiting—Sorafenib—liver cancer	9.66e-05	0.00139	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—liver cancer	9.62e-05	0.00138	CcSEcCtD
Temsirolimus—Rash—Sorafenib—liver cancer	9.58e-05	0.00137	CcSEcCtD
Temsirolimus—Dermatitis—Sorafenib—liver cancer	9.57e-05	0.00137	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—liver cancer	9.52e-05	0.00137	CcSEcCtD
Temsirolimus—Headache—Sorafenib—liver cancer	9.52e-05	0.00137	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—liver cancer	9.5e-05	0.00136	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—liver cancer	9.36e-05	0.00134	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—liver cancer	9.32e-05	0.00134	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—liver cancer	9.23e-05	0.00132	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—liver cancer	9.23e-05	0.00132	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—liver cancer	9.2e-05	0.00132	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—liver cancer	9.18e-05	0.00132	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—liver cancer	9.14e-05	0.00131	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—liver cancer	9.14e-05	0.00131	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—liver cancer	9.12e-05	0.00131	CcSEcCtD
Temsirolimus—Nausea—Sorafenib—liver cancer	9.03e-05	0.00129	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—liver cancer	8.93e-05	0.00128	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—liver cancer	8.91e-05	0.00128	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—liver cancer	8.86e-05	0.00127	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—liver cancer	8.8e-05	0.00126	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—liver cancer	8.8e-05	0.00126	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—liver cancer	8.79e-05	0.00126	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—liver cancer	8.73e-05	0.00125	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—liver cancer	8.66e-05	0.00124	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—liver cancer	8.58e-05	0.00123	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—liver cancer	8.56e-05	0.00123	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—liver cancer	8.56e-05	0.00123	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—liver cancer	8.54e-05	0.00123	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—liver cancer	8.54e-05	0.00123	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—liver cancer	8.49e-05	0.00122	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—liver cancer	8.44e-05	0.00121	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—liver cancer	8.4e-05	0.0012	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—liver cancer	8.3e-05	0.00119	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—liver cancer	8.27e-05	0.00119	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—liver cancer	8.26e-05	0.00118	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—liver cancer	8.24e-05	0.00118	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—liver cancer	8.19e-05	0.00118	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—liver cancer	8.15e-05	0.00117	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—liver cancer	8.15e-05	0.00117	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—liver cancer	8.08e-05	0.00116	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—liver cancer	8.01e-05	0.00115	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—liver cancer	7.94e-05	0.00114	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—liver cancer	7.92e-05	0.00114	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—liver cancer	7.92e-05	0.00114	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—liver cancer	7.92e-05	0.00114	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—liver cancer	7.84e-05	0.00113	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—liver cancer	7.81e-05	0.00112	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—liver cancer	7.79e-05	0.00112	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—liver cancer	7.77e-05	0.00111	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—liver cancer	7.77e-05	0.00111	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—liver cancer	7.75e-05	0.00111	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—liver cancer	7.68e-05	0.0011	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—liver cancer	7.64e-05	0.0011	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—liver cancer	7.47e-05	0.00107	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—liver cancer	7.39e-05	0.00106	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—liver cancer	7.34e-05	0.00105	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—liver cancer	7.33e-05	0.00105	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—liver cancer	7.26e-05	0.00104	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—liver cancer	7.22e-05	0.00104	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—liver cancer	7.2e-05	0.00103	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—liver cancer	7.19e-05	0.00103	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—liver cancer	7.17e-05	0.00103	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—liver cancer	7.17e-05	0.00103	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—liver cancer	7.14e-05	0.00102	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—liver cancer	7.12e-05	0.00102	CcSEcCtD
Temsirolimus—Chills—Epirubicin—liver cancer	7.09e-05	0.00102	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—liver cancer	6.92e-05	0.000993	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—liver cancer	6.92e-05	0.000992	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—liver cancer	6.88e-05	0.000987	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—liver cancer	6.88e-05	0.000987	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—liver cancer	6.83e-05	0.00098	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—liver cancer	6.79e-05	0.000973	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—liver cancer	6.74e-05	0.000966	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—liver cancer	6.66e-05	0.000955	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—liver cancer	6.64e-05	0.000952	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—liver cancer	6.61e-05	0.000947	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—liver cancer	6.59e-05	0.000945	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—liver cancer	6.56e-05	0.000941	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—liver cancer	6.41e-05	0.000919	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—liver cancer	6.37e-05	0.000913	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—liver cancer	6.37e-05	0.000913	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—liver cancer	6.36e-05	0.000912	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—liver cancer	6.23e-05	0.000894	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—liver cancer	6.16e-05	0.000883	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—liver cancer	6.16e-05	0.000883	CcSEcCtD
Temsirolimus—Cough—Epirubicin—liver cancer	6e-05	0.000861	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—liver cancer	5.96e-05	0.000855	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—liver cancer	5.94e-05	0.000852	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—liver cancer	5.88e-05	0.000844	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—liver cancer	5.86e-05	0.00084	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—liver cancer	5.86e-05	0.00084	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—liver cancer	5.86e-05	0.00084	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—liver cancer	5.84e-05	0.000837	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.82e-05	0.000834	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—liver cancer	5.7e-05	0.000817	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—liver cancer	5.62e-05	0.000805	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—liver cancer	5.62e-05	0.000805	CcSEcCtD
Temsirolimus—Infection—Epirubicin—liver cancer	5.58e-05	0.0008	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—liver cancer	5.56e-05	0.000797	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—liver cancer	5.52e-05	0.000791	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—liver cancer	5.51e-05	0.00079	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—liver cancer	5.5e-05	0.000789	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—liver cancer	5.5e-05	0.000788	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—liver cancer	5.45e-05	0.000782	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—liver cancer	5.42e-05	0.000777	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—liver cancer	5.42e-05	0.000777	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—liver cancer	5.42e-05	0.000777	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—liver cancer	5.4e-05	0.000775	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.38e-05	0.000772	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—liver cancer	5.35e-05	0.000768	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—liver cancer	5.2e-05	0.000745	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—liver cancer	5.2e-05	0.000745	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—liver cancer	5.16e-05	0.00074	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—liver cancer	5.12e-05	0.000734	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—liver cancer	5.1e-05	0.000731	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—liver cancer	5.09e-05	0.00073	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—liver cancer	5.08e-05	0.000728	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—liver cancer	5.05e-05	0.000724	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—liver cancer	5.01e-05	0.000718	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—liver cancer	4.99e-05	0.000716	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—liver cancer	4.95e-05	0.00071	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—liver cancer	4.88e-05	0.0007	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—liver cancer	4.85e-05	0.000695	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—liver cancer	4.84e-05	0.000694	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—liver cancer	4.8e-05	0.000689	CcSEcCtD
Temsirolimus—Pain—Epirubicin—liver cancer	4.8e-05	0.000689	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.73e-05	0.000679	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—liver cancer	4.7e-05	0.000674	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—liver cancer	4.63e-05	0.000664	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—liver cancer	4.62e-05	0.000662	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—liver cancer	4.59e-05	0.000659	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—liver cancer	4.52e-05	0.000648	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—liver cancer	4.49e-05	0.000643	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—liver cancer	4.48e-05	0.000642	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—liver cancer	4.44e-05	0.000637	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—liver cancer	4.44e-05	0.000637	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—liver cancer	4.44e-05	0.000637	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—liver cancer	4.44e-05	0.000637	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—liver cancer	4.25e-05	0.000609	CcSEcCtD
Temsirolimus—Hypersensitivity—Epirubicin—liver cancer	4.14e-05	0.000593	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—liver cancer	4.11e-05	0.000589	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—liver cancer	4.11e-05	0.000589	CcSEcCtD
Temsirolimus—Asthenia—Epirubicin—liver cancer	4.03e-05	0.000578	CcSEcCtD
Temsirolimus—Pruritus—Epirubicin—liver cancer	3.97e-05	0.00057	CcSEcCtD
Temsirolimus—Diarrhoea—Epirubicin—liver cancer	3.84e-05	0.000551	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—liver cancer	3.83e-05	0.000549	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—liver cancer	3.73e-05	0.000535	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—liver cancer	3.71e-05	0.000533	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—liver cancer	3.68e-05	0.000527	CcSEcCtD
Temsirolimus—Vomiting—Epirubicin—liver cancer	3.57e-05	0.000512	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—liver cancer	3.56e-05	0.00051	CcSEcCtD
Temsirolimus—Rash—Epirubicin—liver cancer	3.54e-05	0.000508	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—liver cancer	3.54e-05	0.000507	CcSEcCtD
Temsirolimus—Headache—Epirubicin—liver cancer	3.52e-05	0.000505	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—liver cancer	3.44e-05	0.000493	CcSEcCtD
Temsirolimus—Nausea—Epirubicin—liver cancer	3.34e-05	0.000478	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—liver cancer	3.3e-05	0.000474	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—liver cancer	3.28e-05	0.00047	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—liver cancer	3.27e-05	0.000469	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—liver cancer	3.26e-05	0.000467	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—liver cancer	3.09e-05	0.000443	CcSEcCtD
Temsirolimus—CYP3A4—Metabolism—EPT1—liver cancer	7.37e-06	0.000141	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	7.33e-06	0.00014	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTA3—liver cancer	7.31e-06	0.000139	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GLUL—liver cancer	7.26e-06	0.000139	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CPT1B—liver cancer	7.26e-06	0.000139	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	7.03e-06	0.000134	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NR1H4—liver cancer	7e-06	0.000134	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TAT—liver cancer	6.99e-06	0.000133	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYCS—liver cancer	6.95e-06	0.000133	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CD—liver cancer	6.92e-06	0.000132	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTA3—liver cancer	6.89e-06	0.000131	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SERPINE1—liver cancer	6.84e-06	0.000131	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GOT1—liver cancer	6.82e-06	0.00013	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GGT1—liver cancer	6.82e-06	0.00013	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	6.74e-06	0.000129	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	6.73e-06	0.000128	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTA4—liver cancer	6.68e-06	0.000128	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PRKCE—liver cancer	6.66e-06	0.000127	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—STAT3—liver cancer	6.65e-06	0.000127	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HPGDS—liver cancer	6.58e-06	0.000126	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTA2—liver cancer	6.51e-06	0.000124	CbGpPWpGaD
Temsirolimus—MTOR—Disease—APC—liver cancer	6.32e-06	0.000121	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF2—liver cancer	6.31e-06	0.00012	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDH1—liver cancer	6.3e-06	0.00012	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTA4—liver cancer	6.3e-06	0.00012	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTA1—liver cancer	6.28e-06	0.00012	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	6.28e-06	0.00012	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	6.23e-06	0.000119	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NAT2—liver cancer	6.21e-06	0.000119	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—liver cancer	6.18e-06	0.000118	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RAF1—liver cancer	6.18e-06	0.000118	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFB1—liver cancer	6.17e-06	0.000118	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTA2—liver cancer	6.14e-06	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTP1—liver cancer	6.12e-06	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HMOX1—liver cancer	6.04e-06	0.000115	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MTOR—liver cancer	6.03e-06	0.000115	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CB—liver cancer	6.03e-06	0.000115	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CD—liver cancer	6.02e-06	0.000115	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—liver cancer	5.98e-06	0.000114	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALDOB—liver cancer	5.96e-06	0.000114	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—liver cancer	5.94e-06	0.000113	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTA1—liver cancer	5.92e-06	0.000113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CSF2—liver cancer	5.89e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PSMA4—liver cancer	5.87e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PSMD10—liver cancer	5.87e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NAT2—liver cancer	5.85e-06	0.000112	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—H2AFX—liver cancer	5.81e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—liver cancer	5.74e-06	0.00011	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	5.72e-06	0.000109	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—liver cancer	5.71e-06	0.000109	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GOT2—liver cancer	5.71e-06	0.000109	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CRABP1—liver cancer	5.68e-06	0.000108	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	5.68e-06	0.000108	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1B—liver cancer	5.66e-06	0.000108	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTM1—liver cancer	5.63e-06	0.000107	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALDOB—liver cancer	5.61e-06	0.000107	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CD—liver cancer	5.56e-06	0.000106	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CASP3—liver cancer	5.55e-06	0.000106	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—liver cancer	5.54e-06	0.000106	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	5.54e-06	0.000106	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SERPINE1—liver cancer	5.5e-06	0.000105	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—liver cancer	5.49e-06	0.000105	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—liver cancer	5.4e-06	0.000103	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—JUN—liver cancer	5.39e-06	0.000103	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—RAF1—liver cancer	5.37e-06	0.000103	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP2E1—liver cancer	5.37e-06	0.000102	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CRABP1—liver cancer	5.36e-06	0.000102	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—liver cancer	5.35e-06	0.000102	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP1A1—liver cancer	5.33e-06	0.000102	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—liver cancer	5.27e-06	0.000101	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—liver cancer	5.25e-06	0.0001	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—liver cancer	5.25e-06	0.0001	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CB—liver cancer	5.25e-06	0.0001	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—liver cancer	5.24e-06	0.0001	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1A—liver cancer	5.22e-06	9.97e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK8—liver cancer	5.1e-06	9.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—liver cancer	5.08e-06	9.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYCS—liver cancer	5.02e-06	9.58e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—MTHFR—liver cancer	4.97e-06	9.49e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HPGDS—liver cancer	4.97e-06	9.48e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RAF1—liver cancer	4.96e-06	9.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GGT1—liver cancer	4.93e-06	9.4e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GOT1—liver cancer	4.93e-06	9.4e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1B—liver cancer	4.92e-06	9.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARA—liver cancer	4.88e-06	9.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—liver cancer	4.88e-06	9.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—liver cancer	4.86e-06	9.28e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—liver cancer	4.86e-06	9.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CB—liver cancer	4.84e-06	9.24e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—liver cancer	4.82e-06	9.19e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—liver cancer	4.8e-06	9.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK14—liver cancer	4.77e-06	9.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CPT1B—liver cancer	4.75e-06	9.06e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GLUL—liver cancer	4.75e-06	9.06e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—liver cancer	4.71e-06	8.98e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—liver cancer	4.69e-06	8.94e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ESR1—liver cancer	4.68e-06	8.93e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HPGDS—liver cancer	4.68e-06	8.93e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	4.68e-06	8.92e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—liver cancer	4.66e-06	8.89e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—liver cancer	4.65e-06	8.87e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—liver cancer	4.65e-06	8.87e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—F2—liver cancer	4.62e-06	8.83e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NR1H4—liver cancer	4.58e-06	8.74e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1B—liver cancer	4.54e-06	8.67e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1A—liver cancer	4.54e-06	8.67e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA3—liver cancer	4.5e-06	8.59e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—liver cancer	4.48e-06	8.56e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK8—liver cancer	4.43e-06	8.46e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PSMA4—liver cancer	4.43e-06	8.45e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PSMD10—liver cancer	4.43e-06	8.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APC—liver cancer	4.43e-06	8.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CG—liver cancer	4.43e-06	8.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—liver cancer	4.43e-06	8.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HMOX1—liver cancer	4.36e-06	8.33e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—liver cancer	4.33e-06	8.26e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFB1—liver cancer	4.32e-06	8.24e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GOT2—liver cancer	4.31e-06	8.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—liver cancer	4.31e-06	8.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—liver cancer	4.29e-06	8.19e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—liver cancer	4.29e-06	8.18e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	4.22e-06	8.06e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—liver cancer	4.19e-06	8e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CG—liver cancer	4.18e-06	7.97e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PSMA4—liver cancer	4.17e-06	7.96e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PSMD10—liver cancer	4.17e-06	7.96e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—liver cancer	4.16e-06	7.94e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA4—liver cancer	4.12e-06	7.86e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—liver cancer	4.07e-06	7.76e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GOT2—liver cancer	4.06e-06	7.74e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—liver cancer	4.05e-06	7.74e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP2E1—liver cancer	4.05e-06	7.73e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARG—liver cancer	4.03e-06	7.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA2—liver cancer	4.01e-06	7.66e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—liver cancer	4e-06	7.64e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CD—liver cancer	3.89e-06	7.42e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA1—liver cancer	3.87e-06	7.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1A1—liver cancer	3.86e-06	7.36e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SERPINE1—liver cancer	3.85e-06	7.34e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NAT2—liver cancer	3.83e-06	7.31e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	3.82e-06	7.29e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP2E1—liver cancer	3.82e-06	7.28e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYCS—liver cancer	3.79e-06	7.23e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—liver cancer	3.74e-06	7.14e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GGT1—liver cancer	3.72e-06	7.09e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GOT1—liver cancer	3.72e-06	7.09e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—liver cancer	3.68e-06	7.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CD—liver cancer	3.67e-06	7.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDOB—liver cancer	3.67e-06	7e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALB—liver cancer	3.63e-06	6.92e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MTHFR—liver cancer	3.59e-06	6.86e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYCS—liver cancer	3.57e-06	6.81e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—liver cancer	3.56e-06	6.79e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARA—liver cancer	3.53e-06	6.73e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GGT1—liver cancer	3.5e-06	6.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GOT1—liver cancer	3.5e-06	6.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CRABP1—liver cancer	3.5e-06	6.68e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—liver cancer	3.48e-06	6.64e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—liver cancer	3.48e-06	6.64e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAF1—liver cancer	3.47e-06	6.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFB1—liver cancer	3.47e-06	6.62e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—liver cancer	3.4e-06	6.49e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CB—liver cancer	3.39e-06	6.47e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—liver cancer	3.34e-06	6.37e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HMOX1—liver cancer	3.29e-06	6.28e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—liver cancer	3.25e-06	6.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—liver cancer	3.21e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CB—liver cancer	3.2e-06	6.11e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—liver cancer	3.2e-06	6.1e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1B—liver cancer	3.18e-06	6.07e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—liver cancer	3.15e-06	6.01e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—liver cancer	3.12e-06	5.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—liver cancer	3.11e-06	5.94e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HMOX1—liver cancer	3.1e-06	5.92e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—liver cancer	3.07e-06	5.86e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGDS—liver cancer	3.06e-06	5.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—liver cancer	3.04e-06	5.79e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—liver cancer	3.03e-06	5.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CG—liver cancer	3.02e-06	5.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—liver cancer	3.01e-06	5.74e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—liver cancer	3e-06	5.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—liver cancer	2.96e-06	5.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—liver cancer	2.95e-06	5.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—liver cancer	2.95e-06	5.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—liver cancer	2.94e-06	5.6e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARG—liver cancer	2.91e-06	5.56e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1A1—liver cancer	2.91e-06	5.55e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—liver cancer	2.89e-06	5.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK8—liver cancer	2.87e-06	5.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—liver cancer	2.83e-06	5.4e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1A1—liver cancer	2.74e-06	5.23e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—liver cancer	2.73e-06	5.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PSMD10—liver cancer	2.73e-06	5.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PSMA4—liver cancer	2.73e-06	5.21e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MTHFR—liver cancer	2.71e-06	5.18e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARA—liver cancer	2.66e-06	5.08e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CD—liver cancer	2.65e-06	5.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GOT2—liver cancer	2.65e-06	5.06e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—liver cancer	2.65e-06	5.05e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—liver cancer	2.62e-06	5e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALB—liver cancer	2.62e-06	5e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—liver cancer	2.61e-06	4.99e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—liver cancer	2.61e-06	4.98e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MTHFR—liver cancer	2.56e-06	4.88e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARA—liver cancer	2.51e-06	4.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2E1—liver cancer	2.49e-06	4.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—liver cancer	2.44e-06	4.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFB1—liver cancer	2.43e-06	4.64e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—liver cancer	2.41e-06	4.6e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYCS—liver cancer	2.33e-06	4.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CB—liver cancer	2.31e-06	4.42e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GOT1—liver cancer	2.29e-06	4.37e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GGT1—liver cancer	2.29e-06	4.37e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CG—liver cancer	2.28e-06	4.35e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—liver cancer	2.25e-06	4.29e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARG—liver cancer	2.2e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CG—liver cancer	2.15e-06	4.1e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARG—liver cancer	2.07e-06	3.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—liver cancer	2.07e-06	3.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—liver cancer	2.06e-06	3.93e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HMOX1—liver cancer	2.03e-06	3.87e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CD—liver cancer	2e-06	3.82e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—liver cancer	2e-06	3.82e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALB—liver cancer	1.98e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—liver cancer	1.95e-06	3.72e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—liver cancer	1.91e-06	3.65e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—liver cancer	1.89e-06	3.61e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CD—liver cancer	1.89e-06	3.6e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALB—liver cancer	1.86e-06	3.56e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—liver cancer	1.83e-06	3.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1A1—liver cancer	1.79e-06	3.42e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CB—liver cancer	1.75e-06	3.33e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—liver cancer	1.69e-06	3.22e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTHFR—liver cancer	1.67e-06	3.19e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CB—liver cancer	1.65e-06	3.14e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARA—liver cancer	1.64e-06	3.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—liver cancer	1.59e-06	3.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—liver cancer	1.41e-06	2.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CG—liver cancer	1.4e-06	2.68e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARG—liver cancer	1.35e-06	2.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CD—liver cancer	1.23e-06	2.36e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALB—liver cancer	1.22e-06	2.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—liver cancer	1.15e-06	2.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CB—liver cancer	1.08e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—liver cancer	1.06e-06	2.03e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—liver cancer	1e-06	1.91e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—liver cancer	8.69e-07	1.66e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—liver cancer	8.19e-07	1.56e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—liver cancer	6.56e-07	1.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—liver cancer	5.36e-07	1.02e-05	CbGpPWpGaD
